Sweden's Karo Bio has trimmed its staff by 14 workers, mostly in administration and R&D, as part of a shakeup aimed at cutting costs as it pushes its pipeline candidates along. Its lead therapy, KB2115 for dyslipidemia, is in Phase II clinical development. "We will focus on the programs where we have the best chance to deliver visible progress. Naturally, we regret that some of our loyal staff have to leave the company in connection with this process," says Per Olof Wallström, president of Karo Bio. Release